Background/Aims: Behçet’s disease (BD) with intestinal lesions and Crohn’s disease (CD) share clinical features. However, no report has compared the 2 diseases with regard to lesions of the upper gastrointestinal tract (UGT). We aimed to evaluate endoscopic and histologic findings of UGT in CD and BD. Methods: We retrospectively assessed the endoscopic records and biopsy samples of 84 Helicobacter pylori-negative patients (50 CD, 34 BD). In duodenal samples, MUC5AC immunohistochemical analysis was performed to identify gastric foveolar metaplasia. Results: In endoscopic findings, bamboo joint-like appearance (17/50 CD, 0/34 BD) and erosions (14/50 CD, 2/34 BD) were significantly more frequent in CD gastric lesions (p < 0.001, and p = 0.012). In histologic findings of stomach, focal neutrophil infiltration in lamina propria (15/48 CD, 1/34 BD) was significantly more frequent in CD (p < 0.001). In that of duodenum, wide gastric foveolar metaplasia (19/49 CD, 1/34 BD) was significantly more frequent in CD duodenal lesions (p = 0.013). The mean maximum width of the gastric foveolar metaplasia was 114.0 ± 10.6 and 29.5 ± 4.5 μm for CD and BD respectively (p = 0.003). Conclusions: In H. pylori-negative patients, gastric focal neutrophil infiltration and wide duodenal gastric foveolar metaplasia were important for distinguishing CD from BD.

Journal Section:
Original Paper
Keywords:
Upper gastrointestinal tract, Crohn’s disease, Behçet’s disease, Histology, Differential diagnosis
1.
Hardee S, Alper A, Pashankar DS, Morotti RA: Histopathology of duodenal mucosal lesions in pediatric patients with inflammatory bowel disease: statistical analysis to identify distinctive features. Pediatr Dev Pathol 2014; 17: 450–454.
2.
Sakuraba A, Iwao Y, Matsuoka K, Naganuma M, Ogata H, Kanai T, Hibi T: Endoscopic and pathologic changes of the upper gastrointestinal tract in Crohn’s disease. Biomed Res Int 2014; 2014: 610767.
3.
Wright CL, Riddell RH: Histology of the stomach and duodenum in Crohn’s disease. Am J Surg Pathol 1998; 22: 383–390.
4.
Ushiku T, Moran CJ, Lauwers, GY: Focally enhanced gastritis in newly diagnosed pediatric inflammatory bowel disease. Am J Surg Pathol 2013; 37: 1882–1888.
5.
Xin W, Greenson JK: The clinical significance of focally enhanced gastritis. Am J Surg Pathol 2004; 28: 1347–1351.
6.
Magalhaes-Costa MH, Reis BR, Chagas VL, Nunes T, Souza HS, Zaltman C: Focal enhanced gastritis and macrophage microaggregates in the gastric mucosa: potential role in the differential diagnosis between Crohn’s disease and ulcerative colitis. Arq Gastroenterol 2014; 51: 276–282.
7.
Ideguchi H, Suda A, Takeno M, Miyagi R, Ueda A, Ohno S, Ishigatsubo Y: Gastrointestinal manifestations of Behçet’s disease in Japan: a study of 43 patients. Rheumatol Int 2014; 34: 851–856.
8.
Valenti S, Gallizzi R, De Vivo D, Romano C: Intestinal Behçet’s and Crohn’s disease: two sides of the same coin. Pediatr Rheumatol Online J 2017; 15: 33.
9.
Lee JM, Lee KM: Endoscopic diagnosis and differentiation of inflammatory bowel disease. Clin Endosc 2016; 49: 370–375.
10.
Anti M, Marra G, Rapaccini GL, Barone C, Manna R, Bochicchio GB, Fedeli G: Esophageal involvement in Behçet’s syndrome. J Clin Gastroenterol 1986; 8: 514–519.
11.
Houman MH, Ben Ghorbel I, Lamloum M, Khanfir M, Braham A, Haouet S, Sayem N, Lassoued H, Miled M: Esophageal involvement in Behçet’s disease. Yonsei Med J 2002; 43: 457–460.
12.
Ebert EC: Gastrointestinal manifestations of Behçet’s disease. Dig Dis Sci 2009; 54: 201–207.
13.
Yao T, Matsui T, Hiwatashi N: Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000; 43(10 suppl): S85–S93.
14.
Ueno F, Matsui T, Matsumoto T, Matsuoka K, Watanabe M, Hibi T: Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. J Gastroenterol 2013; 48: 31–72.
15.
Mizushima Y: Recent research into Behçet’s disease in Japan. Int J Tissue React 1998; 10: 59–65.
16.
Suzuki Kurokawa M, Suzuki N: Behcet’s disease. Clin Exp Med 2004; 4: 10–20.
17.
Hommes DW, van Deventer SJ: Endoscopy in inflammatory bowel diseases. Gastroenterology 2004; 126: 1561–1573.
18.
Forbees C, Swearingen C, Yazici Y: Behcet’s syndrome activity score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Behcet’s Disease Current Activity Form (BDCAF). Arthritis Rheum 2008; 58(suppl 9): S854–S855.
19.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749–753.
20.
Lee SK, Kim BK, Kim TI, Kim WH: Differential diagnosis of intestinal Behcet’s disease and Crohn’s disease by colonoscopic findings. Endoscopy 2009; 41: 9–16.
21.
Fujiya M, Sakatani A, Dokoshi T, Tanaka K, Ando K, Ueno N, Gotoh T, Kashima S, Tominaga M, Inaba Y, Ito T, Moriichi K, Tanabe H, Ikuta K, Ohtake T, Yokota K, Watari J, Saitoh Y, Kohgo Y: A bamboo joint-like appearance is a characteristic finding in the upper gastrointestinal tract of Crohn’s disease patients: a case-control study. Medicine (Baltimore) 2015; 94: 1–7.
22.
Hirokawa M, Shimizu M, Terayama K, Tamai M, Takeda M, Iida M, Manabe T: Bamboo-joint-like appearance of the stomach: a histopathological study. APMIS 1999; 107: 951–956.
23.
Nomura Y, Moriichi K, Fujiya M, Okumura T: The endoscopic findings of the upper gastrointestinal tract in patients with Crohn’s disease. Clin J Gastroenterol 2017; 10: 289–296.
24.
Yi SW, Cheon JH, Kim JH, Lee SK, Kim TI, Lee YC, Kim WH: The prevalence and clinical characteristics of esophageal involvement in patients with Behcet’s disease: a single center experience in Korea. J Korean Med Sci 2009; 24: 52–56.
25.
Sonnenberg A, Melton SD, Genta RM: Frequent occurrence of gastritis and duodenitis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 39–44.
26.
Carmack SW, Genta RM: The diagnostic value of the duodenal biopsy: a clinico-pathologic analysis of 28,000 patients. Dig Liver Dis 2010; 42: 485–489.
27.
Genta RM, Kinsey RS, Singhal A, Suterwala S: Gastric foveolar metaplasia and gastric heterotopia in the duodenum: no evidence of an etiologic role for Helicobacter pylori. Hum Pathol 2010; 41: 1593–1600.
28.
Schmitz-Moormann P, Malchow H, Pittner PM: Endoscopic and bioptic study of the upper gastrointestinal tract in Crohn’s disease patients. Pathol Res Pract 1985; 179: 377–387.
29.
Shaoul R, Marcon P, Okada Y, Cutz E, Forstner G: The pathogenesis of duodenal gastric metaplasia: the role of local goblet cell transformation. Gut 2000; 46: 632–638.
30.
Taha AS, Dahill S, Nakshabendi I, Lee FD, Sturrock RD, Russell RI: Duodenal histology, ulceration, and Helicobacter pylori in the presence or absence of non-steroidal anti-inflammatory drugs. Gut 1993; 34: 1162–1166.
31.
Walker MM, Crabtree JE: Helicobacter pylori infection and the pathogenesis of duodenal ulceration. Ann N Y Acad Sci 1998; 859: 96–111.
32.
Lim LG, Neumann J, Hansen T, Goetz M, Hoffman A, Neurath MF, Galle PR, Chan YH, Kiesslich R, Watson AJ: Confocal endomicroscopy identifies loss of local barrier function in the duodenum of patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2014; 20: 892–900.
33.
Martini E, Krug SM, Siegmund B, Neurath MF, Becker C: Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol 2017; 4: 33–46.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.